Zeilemaker joins Immunicum with a breadth of experience in science-based business transactions and a refined knowledge and understanding of oncology-based biotech companies. He will report to Carlos de Sousa, CEO of Immunicum.
“Sijme's previous experiences in each layer of the business development process and the oncology landscape will greatly contribute to our ability as a leadership team to more actively engage with potential partners, a key aspect of our corporate strategy," said Carlos de Sousa, CEO of Immunicum.
“His insight and network of cancer-focused biotechnology companies as well as connections to big pharma will provide the fundamental support needed for Immunicum as we advance our programs and further evolve as a company.”
“I am very much looking forward to being an active part of the Immunicum team,” said Sijme Zeilemaker. “I truly believe in the great potential of Immunicum's immuno-oncology therapeutic approach and highly appreciate the opportunity to join and support the company in its next stage of development.”
Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities.
Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted over €7.5m in non-dilutive funding. Sijme obtained a Masters degree in Biomedical Sciences from Leiden University, The Netherlands.
